Avacta FY25 puts AVCT on a clock: £16.9m cash, two Phase 1 reads, one shot

Avacta Group plc (AIM: AVCT), the London and Philadelphia headquartered clinical stage biopharmaceutical company, today released unaudited preliminary results for the year ended 31 December 2025, confirming its repositioning as a pure-play oncology business built around the proprietary pre|CISION peptide drug conjugate platform. The Group ended FY25 with cash and short-term deposits of £16.9 million, against £12.9 million a year earlier, and supplemented that position in March 2026 with an oversubscribed £10 million placing and subscription that extends runway into early Q1 2027. Avacta Group now has two clinical programmes in active enrolment, faridoxorubicin (AVA6000) in a Phase 1b expansion and FAP-Exd (AVA6103) in the Phase 1 FOCUS-01 study, with the next material data readouts expected in H1 and late H2 2026 respectively. The shares have re-rated sharply over the past twelve months, last trading at 86.90p on 14 May 2026 against a 52-week range of 26.00p to roughly 90.50p, leaving today’s results as the first formal opportunity for the market to test whether the operational narrative justifies a market capitalisation pressing close to £390 million.

How does the Avacta Group pre|CISION platform pivot reshape its identity as a pure-play oncology biopharmaceutical company?

The most consequential strategic message in the FY25 disclosure is not a single trial result but the completed transformation of Avacta Group plc into a focused oncology therapeutics business. Management has steadily exited diagnostics adjacencies in earlier reporting cycles, and FY25 frames the company entirely around the pre|CISION technology, a fibroblast activation protein dependent cleavage mechanism designed to release cytotoxic payloads selectively inside the tumour microenvironment. Avacta Group now operates three pipeline generations from a single platform, Gen One faridoxorubicin (AVA6000), Gen Two FAP-Exd (AVA6103), and Gen Three dual payload AVA6207. For an AIM listed clinical stage biotech, narrative consolidation matters as much as scientific validation, because institutional investors and licensing counterparties will only build conviction around a coherent story.

The competitive significance is that Avacta Group is positioning pre|CISION as a successor architecture to antibody drug conjugates, the modality currently dominated by Daiichi Sankyo and AstraZeneca with Enhertu and Datroway. Management has now twice presented preclinical and translational comparisons of AVA6103 against both branded ADCs, including data at the American Association of Cancer Research Annual Congress in San Diego in April 2026. The risk in that positioning is obvious. Enhertu generated multi-billion-dollar revenues in 2025 and is supported by extensive Phase 3 evidence, while AVA6103 is a single Phase 1 asset with no efficacy data in humans. The signalling work, however, is rational. It tells potential pharma partners that Avacta Group is targeting the same indications and the same payload classes that the ADC franchises already validated commercially.

What do the Phase 1 FOCUS-01 enrolment milestone and Tempus AI collaboration mean for the AVA6103 timeline?

The opening of FOCUS-01 in March 2026, with first patient dosed at United States specialist oncology centres, is the operational achievement that anchors the FY25 narrative. The trial is designed to enrol approximately 144 patients across six advanced solid tumour indications, pancreatic cancer, cervical and vulvar cancers, gastric and gastroesophageal junction cancers, small cell lung cancer, colorectal cancer, and hormone receptor positive breast cancer. The choice of indications was not made by traditional clinical intuition. Avacta Group used its strategic collaboration with Tempus AI to rank solid tumour types based on co-expression of SLFN11, a gene predictive of sensitivity to topoisomerase 1 inhibition, and fibroblast activation protein, the cleavage target of pre|CISION. That biomarker-led indication selection is a methodological differentiator and a piece of the equity story that retail investors have under-priced relative to its commercial implications.

For pharmaceutical partners assessing whether to in-license a Gen Two asset, the Tempus AI underwritten patient selection materially de-risks the Phase 1a dose escalation. If the Bayesian Optimal Interval design used in FOCUS-01 successfully identifies a working dose and regimen in indications already enriched for biological responsiveness, the read-through to Phase 2 design is faster and cheaper than a conventional all comers approach. The execution risk remains real, since initial clinical data from AVA6103 is only anticipated in late H2 2026, and the company has explicitly tied its Q1 2027 cash runway to delivering this readout. A delay in enrolment or a slower data cut would push Avacta Group towards another financing round before the AVA6103 catalyst is in the public domain.

How should investors read the AVA6000 cardiac safety inflection and salivary gland cancer signal in the Phase 1b trial?

The Gen One asset, faridoxorubicin (AVA6000), is the most clinically mature programme in the pipeline and delivered the single most commercially significant regulatory development of the period. Avacta Group secured agreement from health authorities to lift the lifetime maximum dose limit on AVA6000, based on cardiac safety data from the Phase 1 trials. Lifetime dose ceilings are the principal commercial constraint on conventional doxorubicin therapy, since cumulative anthracycline exposure causes irreversible cardiotoxicity. If pre|CISION enabled doxorubicin can demonstrate durable cardiac safety at higher cumulative doses, the addressable patient population expands meaningfully across multiple sarcoma and solid tumour settings.

The clinical signal in salivary gland cancer, where Avacta Group reported encouraging efficacy and safety in earlier disclosures and continues to enrol expansion cohorts, is the second pillar of the AVA6000 thesis. Salivary gland carcinomas are a rare disease setting with high unmet need and limited competition, which gives Avacta Group a defensible regulatory pathway and a logical first indication for accelerated approval discussions. The execution risk is that small cohort signals in rare cancers can revert under expansion, and the wider AVA6000 commercial case depends on follow-on indications. Updated AVA6000 efficacy data from the Phase 1a and 1b cohorts in H1 2026 will be the proximate test.

What does the £32.5 million cash raise and convertible bond renegotiation signal about Avacta Group capital discipline?

Across the last 18 months, Avacta Group has raised £32.5 million in new equity from a combination of £22.5 million during 2025 and the £10 million March 2026 placing, alongside renegotiating the terms of its convertible bond. For a clinical stage AIM company without revenue, this scale of financing in a soft biotech funding environment is itself a strategic signal. The company has demonstrated repeated access to capital markets and has used those proceeds to underwrite specific operational catalysts rather than general working capital extension.

The financial constraint, however, is unchanged. Cash of £16.9 million at the December 2025 balance sheet date, and £16.4 million as of 30 April 2026, against operating cash burn implied by two parallel Phase 1 programmes and a Gen Three development effort, translates into a runway that expires close to the AVA6103 readout window. Strong data would open a much better financing window, while a disappointing readout would force a dilutive raise into a weaker share price. This is the binary that institutional investors will price as 2026 progresses, and it is the lens through which today’s results should be read.

How does the AVCT share price trajectory and AIM small-cap risk profile shape the FY25 narrative?

Avacta Group has been one of the most asymmetric rerating stories on AIM over the past year. The stock traded as low as 26p in 2025 and has reached as high as 90.50p in 2026, last printing 86.90p on 14 May 2026. That implies a market capitalisation of approximately £390 million on around 453.5 million shares in issue and a 12-month return in excess of 140%. Consensus analyst price targets sit below the current market price, with at least one published target around 71.33p, indicating that recent price action has been driven by retail momentum and operational catalysts rather than by upgraded sell-side models.

The structural risk profile remains that of a clinical stage AIM biotech with no commercial revenue, two Phase 1 programmes, and a balance sheet that requires further financing within approximately three quarters. The strategic opportunity is the standing reference in the FY25 statement to continuing partnering discussions on first, second and third generation assets, any of which would convert pre|CISION into a non-dilutive funding mechanism. For senior decision makers and institutional investors, the FY25 results do not change the fundamentals of the Avacta Group case, but they do consolidate it into a coherent pure-play oncology narrative built around three near-term catalysts, AVA6000 H1 2026 efficacy data, AVA6103 late H2 2026 initial clinical data, and a possible partnering announcement on any of the three pre|CISION generations.

Key takeaways on what the Avacta Group FY25 results mean for AVCT shareholders, competitors, and the oncology sector

• Avacta Group plc has completed its transition into a pure-play oncology biopharmaceutical company built around the pre|CISION peptide drug conjugate platform, removing optionality and concentrating execution risk on three pipeline generations.
• Two parallel Phase 1 programmes, faridoxorubicin (AVA6000) and FAP-Exd (AVA6103), provide twin catalyst paths in 2026, with AVA6000 efficacy data in H1 and AVA6103 initial clinical data in late H2.
• The Tempus AI strategic collaboration in FOCUS-01 represents a methodological differentiator, using SLFN11 and fibroblast activation protein co-expression to enrich indication selection for the AVA6103 trial.
• The lifting of the lifetime maximum dose limit on AVA6000 by health authorities is the single most commercially material regulatory event in the period, expanding the addressable Gen One opportunity beyond conventional doxorubicin populations.
• Cash and short-term deposits of £16.9 million at 31 December 2025, supplemented by a £10 million March 2026 placing, extend cash runway into early Q1 2027, aligning financing tightly to the AVA6103 readout window.
• Cumulative equity raises of £32.5 million across 18 months demonstrate repeated market access for Avacta Group, but leave the company exposed to a dilutive raise if the AVA6103 readout disappoints.
• AVCT shares last traded at 86.90p on 14 May 2026, near the 52-week high of approximately 90.50p, with consensus analyst targets below market price, indicating a momentum and catalyst-driven valuation rather than a fundamentals-driven one.
• Strategic positioning of pre|CISION as a successor architecture to antibody drug conjugates such as Enhertu and Datroway is rational signalling to potential pharma partners but carries high evidentiary risk at the current Phase 1 stage.
• Ongoing partnering discussions across Gen One, Gen Two, and Gen Three pre|CISION assets remain the most asymmetric upside catalyst, with the potential to convert platform claims into non-dilutive cash and external validation.
• For the wider United Kingdom AIM biotech sector, Avacta Group is now a reference data point for whether retail-driven momentum can sustain clinical stage valuations into 2026 data readouts.